Hepatitis B Virus Infection in B-Cell Non-Hodgkin's Lymphoma, and Effect of Entecavir in Prophylactic Antiviral Therapy
Health (Irvine, Calif.)
specialized studies on hepatitis B virus (HBV) infection and B-NHL (B-cell Non-Hodg- kin's Lymphoma) are limited, as well as prophylactic antiviral therapy for B-NHL patients with HBV infection who are receiving anticancer chemotherapy. This study aims to investigate the association between HBV infection and B-NHL, and to evaluate the effect of prophylactic antiviral therapy for HBV-infected B-NHL patients. Study design: A retrospective, case-control study was performed. The study group
... study group included 420 patients with B-NHL who were consecutively diagnosed from May 2003 to October 2013 (age range, 14 -71 years), and the control group included 1280 Chinese residents in Guangxi who participated in the Health Survey (age range, 18 -74 years). We compared the prevalence rate of HBV infection and clinic-pathologic characteristics between the two groups. The prevalence rate of HBV infection in our study was 34.7% (146/420), higher than the prevalence rate of 13.9% (178/1280) in the general population (P < 0.001). Among 146 B-NHL patients who received anticancer chemotherapy, 104 patients (71.2%) received prophylactic antiviral therapy. Conclusion: This study provides evidence that HBV may play an important role in development of B-NHL. Entecavir maybe the better antiviral drugs than Lamivudine, and antiviral therapy is maintained more than 6 months that maybe the optimal duration of prophylactic antiviral therapy. But further investigation should be conducted for determination of optimal duration and monitoring of antiviral therapy.